RALB and colitis: A recent work showed that DSS-induced administration of reductively modified albumin (r-Alb) to mice with colitis effectively improved the colitis phenotype by the mechanism that r-Alb inhibits cellular ROS and superoxide production through sulfhydryl (-SH) and reduces the cellular damage caused by oxidative stress.